A therapeutic against crimean-congo hemorrhagic fever virus
AssigneeThomas Jefferson University
InventorsMatthias Johannes Schnell, Gabrielle Scher
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a recombinant vector from an attenuated rabies virus comprising a nucleotide sequence encoding at least one CCHFV glycoprotein and at least one mucin like domain. The disclosure further provides a method for conditioning an immune response with said recombinant virus vector incorporated in said virus virion.
Claims17
A composition comprising a recombinant vector from an attenuated rabies virus comprising a nucleotide sequence encoding at least one Crimean-Congo hemorrhagic fever virus (CCHFV) glycoprotein and a mucin-like domain.
(canceled)
6-15. (canceled)
A method of conditioning an immune response protective against a CCHFV virus in a subject, the method comprising administering to the subject a recombinant vector from an attenuated rabies virus comprising a nucleotide sequence encoding at least one CCHFV glycoprotein and a mucin-like domain.
(canceled)
23-33. (canceled)
A method of treating a subject infected with a CCHFV virus, comprising administering to the subject a composition comprising a recombinant vector from an attenuated rabies virus that expresses at least one CCHFV immunogenic protein and a mucin-like domain, wherein said composition induces an effective immune response against one or both of said viruses wherein the at least one immunogenic CCHFV protein comprises the amino acid sequence of SEQ ID NO:
- 3.
A CCHFV ribonucleic acid (RNA) polynucleotide vaccine, comprising at least one RNA having an open reading frame encoding at least one CCHFV glycoprotein or an immunogenic fragment thereof and a mucin-like domain, and a pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.